

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SHANGHAI JUNSHI BIOSCIENCES CO., LTD.*

上海君實生物醫藥科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 1877)

COMPLETION OF ISSUANCE OF THE 2026 THIRD TRANCHE OF TECHNOLOGY INNOVATION BONDS

This announcement is made by Shanghai Junshi Biosciences Co., Ltd.* (上海君實生物醫藥科技股份有限公司) (the “**Company**”) on a voluntary basis. Reference is also made to the overseas regulatory announcement of the Company dated 21 August 2026.

Reference is made to the announcement dated 28 December 2025 of the Company in relation to the acceptance of registration of the medium term notes by the National Association of Financial Market Institutional Investors (the “**Announcement**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcement.

The board of directors of the Company is pleased to announce that the Company has recently completed the issuance of the 2026 third tranche of technology innovation bonds, and received the funds on 21 August 2026. The 2026 third tranche of technology innovation bonds is issued with a total amount of RMB0.7 billion and a term of 3 years, and shall mature on 21 August 2029 and have an issuance interest rate of 2.55%.

The relevant documents in respect of the issuance of the 2026 third tranche of technology innovation bonds have been published on websites recognised by the National Association of Financial Market Institutional Investors, including the websites of ChinaMoney at <https://www.chinamoney.com.cn>, the Shanghai Clearing House at <https://www.shclearing.com.cn> and the Beijing Financial Assets Exchange at <https://www.cfae.cn>.

Shareholders of the Company and potential investors are advised to exercise cautiously when dealing in the securities of the Company.

By order of the Board
Shanghai Junshi Biosciences Co., Ltd.*
Mr. Xiong Jun
Chairman

Shanghai, the PRC, 21 August 2026

As at the date of this announcement, the Board of Directors of the Company comprises Mr. Xiong Jun, Dr. Li Ning, Dr. Zou Jianjun, Mr. Li Cong, Mr. Zhang Zhuobing, Dr. Wang Gang and Dr. Li Xin as executive Directors; Dr. Yao Sheng and Mr. Tang Yi as non-executive Directors; and Dr. Feng Xiaoyuan, Mr. Li Zhongxian, Ms. Lu Kun, Dr. Yang Jin and Mr. Chen Liang as independent non-executive Directors.

** For identification purposes only*